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 Experimental autoimmune encephalomyelitis (EAE) is
an autoimmune inflammatory disorder leading to primary cen-
tral nervous system demyelination. EAE has been frequently
used as an animal model for testing treatments against mul-
tiple sclerosis (MS) [1-16]. The optic nerve is a frequent site
of involvement in both EAE and MS [17-23]. Reactive oxy-
gen species (ROS) such as superoxide, hydrogen peroxide,
nitric oxide and peroxynitrite are mediators of demyelination
and disruption of the blood-brain barrier (BBB) in EAE [24-
31]. The role ROS play in altering BBB permeability and de-
myelination has been inferred from the beneficial effect of
monotherapy with free radical scavengers or antioxidants on
EAE [27-31]. ROS scavengers include catalase and superox-
ide dismutase (SOD). SOD dismutes superoxide to hydrogen
peroxide (H2O2) and catalase detoxifies the H2O2 to H2O and
O2.
In a prior study, we targeted a single ROS, hydrogen per-
oxide, for detoxification by catalase gene inoculationn [23]. It
reduced demyelination of the optic nerve by 38%. An approxi-
mately one-third suppressive effect on disease activity is
achieved by currently available treatments for MS by utiliz-
ing a single drug [32]. Some studies have suggested that com-
bination therapy may have a better suppressive effect on MS
than monotherapy [33,34] although this is not always the case
[35]. Here, we attempt to further ameliorate EAE by assess-
ing the additional protective effects on experimental optic
neuritis of combining in vivo scavenging of superoxide by
germ line increases in the extracellular superoxide dismutase
(ECSOD) and scavenging of hydrogen peroxide by viral me-
diated gene transfer of the human catalase gene.
METHODS
Recombinant adeno-associated virus:  The adeno-associated
virus (AAV) vector pTR-UF was used to accept the human
catalase cDNA at the Not1 and Sal1 sites. The resulting pTR-
CAT plasmid were amplified, then purified and packaged into
serotype 2 rAAV. Briefly, recombinant AAV was purified
through iodixanol step gradients and heparin-agarose affinity
columns and assayed as previously described [36]. Each virus
preparation contained 1011 to 1012 particles per milliliter and
109 to 1010 infectious center units per milliliter.
Induction of EAE and intraocular injections:  Two µl of
recombinant adeno-associated virus (rAAV) catalase were in-
jected into the vitreous cavity of 20 transgenic ECSOD mice,
overexpressing human extracellular superoxide dismutase
(ECSOD; a generous gift of Dr. James Crapo) and 20 wild-
type littermates were also injected with AAV-catalase as con-
trols. Briefly, ECSOD transgenic mice were constructed by
injection of DNA containing the entire human ECSOD cDNA
driven by a human β-actin promoter that was injected into
pronuclei of fertilized eggs that were isolated from mice
[(C57BL/6xC3H)F1x(C57BL/6xC3H)F1]. Surviving eggs
were implanted into pseudopregnant foster mothers to gener-
©2007 Molecular Vision
Dual gene therapy with extracellular superoxide dismutase and
catalase attenuates experimental optic neuritis
Xiaoping Qi,1 William W. Hauswirth,1,2 John Guy1,3
1Departments of Ophthalmology, Molecular Genetics and 2Microbiology, 3Neurology, University of Florida, College of Medicine,
Gainesville, FL
Purpose: To ameliorate experimental optic neuritis by combining scavenging of superoxide by germ line increases in the
extracellular superoxide dismutase (ECSOD) and hydrogen peroxide by viral-mediated gene transfer of the human cata-
lase gene.
Methods: The human catalase gene inserted into recombinant adeno-associated virus (rAAV) was injected into the right
eyes of transgenic mice overexpressing human ECSOD and wild-type littermates. Animals were simultaneously sensi-
tized for experimental autoimmune encephalomyelitis (EAE) and then sacrificed one month later. The effects of antioxi-
dant genes (ECSOD and catalase) on the histologic lesions of EAE were measured by computerized analysis of myelin
area, optic disc area, extent of the cellular infiltrate, cerium derived H2O2 reaction product and extravasation of serum
albumin detected by immunogold.
Results: Combined scavenging of H2O2 and superoxide with ECSOD and catalase suppressed demyelination by 72%,
54% due to catalase, and 19% due to ECSOD. Disruption of the blood-brain barrier was reduced 63% by the combined
effects of catalase and ECSOD, 35% due to catalase and 29% due to ECSOD.
Conclusions: Transgene modulation of antioxidant enzyme defenses against both superoxide and its metabolite H2O2
provide a substantial suppressive effect against EAE in the optic nerve that may be a new therapeutic strategy for suppres-
sion of optic neuritis and multiple sclerosis.
Correspondence to: Dr. J Guy, Department of Ophthalmology, Uni-
versity of Florida, College of Medicine, Gainesville, FL, 32610;
Phone: (352) 392-3451; FAX: (352) 392-7839; email:
johnguy@eye.ufl.edu
1ate offspring containing the ECSOD transgene. Mice express-
ing human ECSOD were identified using Southern blot analy-
sis of DNA extracted from the tail and probed with the entire
human ECSOD cDNA [37,38]. EAE was induced in the mice
by sensitization with 0.2 cc of ultrasonically homogenized
spinal cord emulsion in complete Freunds adjuvant (Difco,
Detroit, MI) that was injected subdermally into the nuchal area
[30]. Mice were maintained in veterinarian-supervised ani-
mal care facilities that are fully accredited by the American
Association of Laboratory Animal Science and they were hu-
manely cared for in full compliance with ARVO guidelines.
Immunobloting and immunohistochemistry:  Retinal gan-
glion cells (RGC-5) were grown in Dulbecco’s Modified Eagle
Medium (DMEM; Fisher Scientific) supplemented with 10%
heat-inactivated fetal bovine serum and 1% penicillin strepto-
mycin (Sigma) at 37 °C with 5% CO2. Cells were grown in 15
cm dishes that were infected with AAV containing the human
catalase cDNA at multiplicities of infection (MOI) of 5,000
particles per cell. Controls were infected with AAV-GFP. Two
days after AAV infections, cells were harvested. Briefly this
involved washing the trypsinized cells in cold PBS, then manu-
ally homogenizing them. For immunodetection, 15 mg of
homogenated protein was separated on a 10% SDS polyacry-
lamide gel and electro-transferred to a polyvinylidene fluo-
ride membrane (BioRad, Hercules, CA). We immunostained
the membrane with monoclonal anti-catalase antibodies
(Sigma-Aldrich, St. Louis, MO, C0979, mol wt, 60 kDa) and
then goat anti-mouse IgG horseradish peroxidase (HRP) con-
jugated secondary antibodies (Sigma-Aldrich). We detected
complexes using the enhanced chemiluminesence (ECL) sys-
tem (Amersham Pharmacia Biotech, Piscataway, NJ). Anti-
mouse β-actin antibody was used as an internal control for
protein loading.
One month after AAV and EAE inoculations, mice were
overdosed with sodium pentobarbital (0.3 mg/g body weight).
They were then perfused by cardiac puncture with fixative
consisting of 4% paraformaldehyde in 0.1 M PBS buffer (pH
7.4). The eyes with attached optic nerves were dissected out
of ten ECSOD mice and ten littermates. The specimens were
further processed by immersion fixation in 2.5%
gluteraldehyde, postfixed in 1% osmium tetroxide, 0.1 M so-
dium cacodylate-HCl buffer (pH 7.4), 7% sucrose in the cold,
and then dehydrated through an ethanol series to propylene
oxide, infiltrated, and embedded in epoxy resin that was poly-
merized at 60 °C overnight. For immunocytochemistry, tissue
specimens from the other ten ECSOD mice and ten littermates
were postfixed in 5.0% acrolein, 0.1 M sodium cacodylate-
HCl buffer (pH 7.4) and 7% sucrose and then dehydrated
through an ethanol series and embedded in LR-White (Ted
Pella, Redding, PA) that was polymerized at 50°C overnight.
Semi-thin longitudinal sections (0.5 µm) of the optic nerve
head and retrobulbar nerve were stained with toluidine blue
for light microscopic examination. Ultrathin sections (90 nm)
were placed on nickel grids for immunocytochemistry. Non-
specific binding of antibodies was blocked by 5% normal goat
serum in 0.01 M Tris-buffered saline, (pH 7.2) or 2% teleost
gelatin and 2% nonfat dry milk in 0.01 M TBS (pH 7.2) with
TBST for 30 min for albumin immunostaining. They were
then reacted with a rabbit anti-albumin antibody or an ECSOD
antibody (a generous gift of Dr. Stephan Marklund) that rec-
ognizes the human ECSOD [39], but not the murine ECSOD
(personal communications with Dr. Marklund) in the same
buffer for 2 h at room temperature.
After washes in 0.1 M PBS, the specimens were reacted
with the secondary goat anti-rabbit IgG antibodies conjugated
to 10 nm gold or Cy3 for immunofluorescence microscopy.
After washes in buffer, grids were rinsed in deionized water.
For examination at low magnification transmission electron
microscopy, the immunogold particles were enlarged by sil-
ver enhancement using a kit (Ted Pella, Redding, PA) accord-
ing to the manufacturer’s specifications. To check for nonspe-
cific binding of the secondary antibody, control specimens were
incubated in the buffer, followed by the gold-labeled or Cy3
labeled antibody. Immunolabeled and control specimens were
photographed by transmission electron microscopy without
poststaining.
Morphometric analysis:  Morphometric analysis was per-
formed in masked fashion as previously described [23]. Briefly,
images of toluidine blue stained sections of the optic nerve
were captured with a video camera mounted on a light micro-
scope and then the digital image was entered into computer
memory. After initial calibration with a stage micrometer, the
optic nerve head areas were manually traced using NIH IM-
AGE software and a MacIntosh Computer (Apple, Cupertino,
CA). The number of glial cells and inflammatory cells in the
retrobulbar optic nerve were also quantitated by thresholding
of the darker staining cell nuclei. Using electron microscopy,
identification of glial cells in the optic nerve was based on
morphologic criteria. Fibrous astrocytes were identified by
their round or elliptical nuclei with few clumps of chromatin
in a relatively light karyoplasm that was surrounded by a vo-
luminous pale cytoplasm with long processes and glial fila-
ments. Inflammatory cells were identified by the prominent
clumping of nuclear chromatin, ribosome rich cytoplasm that
was clearly more electron dense than that of astrocytes and
the presence of phagosomes with engulfed myelin debris.
Optic nerve specimens were examined without
poststaining using a Hitachi H-7000 transmission electron
microscope (Tokyo, Japan) operating at 75 kV. Photographs
were made at a magnification of 2,500X. For quantitative
analysis, micrographs of each optic nerve were digitized into
computer memory by using a UMAX scanner (UMAX Data
Systems, Fremont, CA). Extravasated serum albumin
immunogold or H2O2 derived cerium perhydroxide were quan-
titated by thresholding the respective elements. Mean particle
counts for each nerve were obtained by taking the mean value
of the 10 micrographs. Each mean value was expressed as the
number of elements per unit area. The extent of demyelina-
tion was quantitated by threshold measurements of the elec-
tron dense myelin sheaths that were derived from the axonal
transmission electron micrographs for each optic nerve. Again
using NIH IMAGE software, we utilized the threshold feature
to outline the myelin sheaths for each micrograph. Glial or
inflammatory cells that were also highlighted in the thresholded
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Figure 1. Expression of extracellular superoxide dismutase and catalase.  Immunofluorescence micrographs show expression of the human
ECSOD (arrows) in the optic nerve of a representative transgenic ECSOD mouse (A), but it is absent in the optic nerve of a wild-type
littermate (B). Transmission electron micrograph of the retrobulbar optic nerve of a transgenic ECSOD mouse reveals ECSOD immunogold
(arrows) in the perivascular space and endothelia of the optic nerve (C), peripapillary choroid (E) and optic nerve sheath (F). Human ECSOD
is absent in wild-type littermates (D). Immunobloting shows increased catalase expression in cultured retinal ganglion cells infected with
rAAV containing the gene for human catalase, relative to control RGC-5 cells infected with AAV-GFP (G). E represents endothelial cell. RBC
represents red blood cell. L represents lumen, Cat represents catalase, gfp represents green fluorescent protein.
3micrographs were removed manually by using the eraser func-
tion. To calculate the outlined myelin area we used the soft-
ware “analyze” feature. Increases in myelin sheath area (less
demyelination) thereby indicated a beneficial treatment effect.
Grouped student t-tests were used to assess differences in the
myelin areas, optic nerve head areas, optic nerve cell counts,
hydrogen peroxide reaction product and extravasated albumin
immunogold between the transgenic ECSOD mice and the
wild-type littermates.
RESULTS
ECSOD and catalase expression:  Expression of the human
ECSOD was evident in the optic nerves of transgenic ECSOD
mice (Figure 1A), but not in the wild-type littermates (Figure
1B). As implied by its name, ECSOD immunogold localized
to the perivascular space and endothelial cells in the optic nerve
(Figure 1C) and peripapillary choroid (Figure 1E). It was also
represented in the meninges comprising the optic nerve sheath
of ECSOD mice (Figure 1F). Human ECSOD immunogold
was absent in the perivascular space of the littermates (Figure
1D). This distribution of ECSOD mirrored the presence of
H2O2 in the EAE optic nerve. Immunobloting showed that reti-
nal ganglion cells infected with rAAV containing the gene for
human catalase had increased catalase expression relative to
controls infected with AAV-GFP (Figure 1G).
Demyelination:  Light microscopy of the EAE optic nerves
revealed foci of demyelination, the hallmark of the histopa-
thology of EAE and MS, was evidenced by loss of toluidine
blue staining. This finding was seen to some degree in all ani-
mals sensitized for EAE. Transmission electron microscopy
clearly demonstrated the benefits of anti-ROS gene therapy.
Illustrative of the benefits of double protection, the right eyes
of ECSOD mice that received the AAV-catalase gene inocula-
tion had much less myelin fiber injury than the unprotected
left eyes of wild-type mice. A representative micrograph of
the right eyes of ECSOD mice further protected by catalase
shows a near normal complement of optic nerve fibers with
relatively preserved myelin lamellae (Figure 2A). These find-
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Figure 2. Suppression of demyelination.  Representative transmission electron micrographs of the retrobulbar optic nerve show many normal
fibers and substantially less demyelinated and thinly myelinated axons following rAAV-catalase inoculation of the right eyes of transgenic
ECSOD mice (A), relative to the unprotected left eyes of wild-type littermates in whom marked fiber loss, naked axons and those with thin
sheaths of myelin were prominent ultrastructural findings (B). The barplot shows mean myelin areas of the retrobulbar optic nerve protected
by both ECSOD and catalase (ECSOD OD), catalase (Wt OD), ECSOD (ECSOD OS) and unprotected EAE (Wt OS; C). Barplot (D) illus-
trates the preservation of myelin induced by ECSOD and catalase, catalase or ECSOD relative to unprotected nerves. Asterisk (*) represents
p<0.05, double asterisks (**) represents p<0.01, Ax represents axon, As represents astrocyte process.
4ings sharply contrasted with the unprotected left eyes of wild-
type littermates where myelin and fiber loss was severe (Fig-
ure 2B). Here remaining axons were degenerating, enveloped
by thin sheaths of myelin, or naked. Optic nerve fibers were
replaced by a proliferation of astroglial processes.
Measurements of myelin area in wild-type mice not sen-
sitized for EAE revealed a mean of 439,683 µm2. This value
was comparable to the normal unsensitized ECSOD transgenic
mouse with a value of 424,878 µm2. Relative to unsensitized
wild-type mice, the myelin area of unprotected wild-type mice
induced with EAE (Wt OS) was reduced by 55% (p<0.03).
Quantitative analysis confirmed that in vivo scavenging of
hydrogen peroxide by viral mediated catalase gene transfer
and superoxide scavenging by ECSOD resulted in a mean
myelin area of 340,236 µm2 (ECSOD OD), thus reducing de-
myelination by 72% relative to a value of 197,517 µm2 (Wt
OS) for untreated wild-type mice with EAE (p<0.01; Figure
2C-D). This combined effect was greater than that of super-
oxide scavenging alone as ECSOD mice had 19% more my-
elin (less demyelination) with a mean myelin area of 235,123
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Figure 3. Suppression of optic disc swelling.  Representative light
micrographs showing catalase and SOD suppressed optic nerve head
edema (A) relative to the unprotected optic nerve (arrows) exhibit-
ing marked swelling of the optic nerve head (B). The barplot of mean
optic nerve head (ONH) areas shows that optic nerve head swelling
(smaller ONH area) was reduced by combined ECSOD and catalase
(ECSOD OD) treatment, catalase treatment (Wt OD), ECSOD treat-
ment (ECSOD OS), but it was greatest with no treatment (Wt OS;
C). Barplot (D) illustrates the reduction in ONH swelling induced by
ECSOD and catalase, catalase or ECSOD relative to unprotected
nerves. Asterisk (*) represents p<0.05, double asterisks (**) repre-
sents p<0.01.
5µm2 (ECSOD OS) than the mean of 197,517 µm2 (Wt OS) for
unprotected wild-type mice (p<0.05). It was also greater than
the solo effect of catalase mediated scavenging of hydrogen
peroxide with a mean myelin area of 304,190 µm2 (Wt OD)
versus 197,517 µm2 (Wt OS) that reduced demyelination by
54% (p<0.01). Relative to unsensitized wild-type mice, my-
elin area was reduced by 23% even with combined scaveng-
ing (ECSOD OD). However, this difference was not statisti-
cally significant. Clearly, double protection against superox-
ide and H2O2 by ECSOD and catalase offered the best protec-
tion against the most desirable parameter sought after for treat-
ment, amelioration of myelin fiber injury in the EAE optic
nerve. The solo effect of catalase was better than that of
ECSOD.
Optic disc edema:  Optic disc edema, seen ophthalmo-
scopically in approximately one-third of patients with acute
optic neuritis or multiple sclerosis, was evident in EAE ani-
mals in which lateral displacement of the peripapillary retina
and filling of the optic cup indicated optic nerve head swell-
ing at the light microscopic level. Relative to ECSOD and
catalase-protected nerves (ECSOD OD; Figure 3A), optic
nerve head swelling was most severe in the unprotected nerves
of wild-type mice (Wt OS; Figure 3B). The combined effects
of in vivo scavenging of hydrogen peroxide by viral mediated
catalase gene transfer and superoxide scavenging by germ line
increases of ECSOD reduced optic nerve head edema by 34%
with a mean optic nerve head area of 29,821 µm2 (ECSOD
OD) relative to wild-type mice with a mean value of 45,354
µm2 (Wt OS; p<0.01; Figure 3C-D). This combined effect was
greater than that of superoxide scavenging alone. ECSOD mice
had 16% less optic disc edema with a mean optic nerve head
area of 38,092 µm2 (ECSOD OS) relative to a mean of 45,354
µm2 (Wt OS) for wild-type mice (p<0.05). Clearly, the addi-
tional benefit of ECSOD was not much greater than the solo
effect of catalase that reduced optic disc edema by 32% with a
mean optic nerve head area of 30,754 µm2 (Wt OD) relative
to 45,354 µm2 for untreated eyes (Wt OS; p<0.01).
Optic nerve cell count:  Mononuclear inflammatory cells
and reactive astroglial cells predominantly involved the ret-
robulbar optic nerve of mice inoculated for EAE. ECSOD eyes
inoculated with catalase had the greatest decrease in optic nerve
cellularity. A representative light micrograph shows no inflam-
matory cells and a relatively normal complement of astroglial
nuclei. (Figure 4A). In contrast, the unprotected nerves re-
©2007 Molecular Vision Molecular Vision 2007; 13:1-11 <http://www.molvis.org/molvis/v13/a1/>
Figure 4. Suppression of cellular infiltration.  Representative light
micrographs show that cellular infiltration in the retrobulbar optic
nerve is reduced by double protection with ECSOD and catalase (A)
relative to the unprotected optic nerve (B). The barplot shows the
mean optic nerve cell count of the retrobulbar optic nerve protected
by both ECSOD and catalase (ECSOD OD), catalase (Wt OD),
ECSOD (ECSOD OS) and unprotected EAE (Wt OS; C). Barplot
(D) illustrates the reduction in the optic nerve cell count induced by
both ECSOD and catalase, catalase or ECSOD relative to unpro-
tected nerves. Asterisk (*) represents p<0.05 double asterisks (**)
represents p<0.01, A represents astrocyte, M represents mononuclear
inflammatory cell.
6vealed many mononuclear inflammatory cells in addition to
the astroglia (Figure 4B). The combined effects of in vivo scav-
enging of hydrogen peroxide by viral mediated catalase gene
transfer and superoxide scavenging suppressed the optic nerve
cell count by 27% with mean of 243 cells per 105 µm2 (ECSOD
OD) relative to 335 cells per 105 µm2 (Wt OS) for untreated
wild-type mice (p<0.01) (Figure 4C-D). This combined effect
was greater than that of superoxide scavenging alone as
ECSOD mice (ECSOD OS) had 17% less inflammation with
a mean cell count of 276 cells per 105 µm2 versus a mean of
335 cells per 105 µm2 for wild-type mice (Wt OS; p<0.05). It
was slightly greater than the solo effect of catalase mediated
scavenging of hydrogen peroxide with a mean cell count of
258 cells per 105 µm2 (Wt OD) relative to 335 cells per 105
µm2 (Wt OS) that reduced inflammation by 23% (p<0.01).
H2O2:  Electron dense cerium derived H2O2 reaction prod-
uct in the EAE optic nerve was greatest in the meninges of the
optic nerve sheath, but was also evident in the optic nerve
head and retrobulbar nerve, thus it was similar to the distribu-
tion of the ECSOD. Transmission electron micrographs show
cerium perhydroxide reaction product in the lumen and perivas-
cular space of ECSOD mice (Figure 5A) is increased relative
to wild-type mice (Figure 5B). In the retrobulbar optic nerve
of AAV-catalase gene inoculated eyes of ECSOD mice
(ECSOD OD) a mean of 62 cerium perhydroxide particles per
2.6x106 µm2 represented a 5% increase of H2O2 counts rela-
tive to 59 particles per 2.6x106 µm2 for unprotected nerves of
wild-type mice (Wt OD; Figure 5C-D). This slight difference
was not statistically significant. Catalase gene inoculation into
the eyes of wild-type mice (Wt OD) with a value of 38 par-
ticles per 2.6x106 µm2 decreased H2O2 counts by 35% relative
to the unprotected eyes of wild-type mice (Wt OS), but this
difference was not statistically significant. However, cerium
perhydroxide reaction product particles increased by 72% in
the left eyes of ECSOD mice (ECSOD OS) with a mean of
106 particles per 2.6x106 µm2 relative to unprotected left eyes
of wild-type mice (Wt OS; p<0.01).
Blood-brain barrier:  Disruption of the blood-brain bar-
rier (BBB), a hallmark of optic neuritis and MS, was seen in
all animals sensitized for EAE. A standard marker of BBB
disruption is the extravasation of serum albumin that was de-
tected by immunolabeling. Transmission electron microscopy
of the optic nerves revealed albumin immunogold labeling in
all animals with EAE. Extravasated albumin immunogold in
the perivascular compartment located the foci of BBB disrup-
tion in EAE. Albumin immunogold confined to the intravas-
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Figure 5. Reactive oxygen species in the optic nerve.  Transmission
electron micrographs show electron dense cerium perhydroxide (ar-
rows) formed by the reaction of cerium chloride and endogenous
hydrogen peroxide is more prominent in the optic nerves of animals
protected by ECSOD (ECSOD OS; A) relative to unprotected nerves
(Wt OS; B). The barplot shows mean cerium perhydroxide particle
counts in the retrobulbar optic nerves protected by ECSOD and cata-
lase (ECSOD OD), catalase (Wt OD), ECSOD (ECSOD OS) or un-
protected EAE (Wt OS; C). Barplot (D) illustrates the relative changes
in H2O2 reaction product counts in nerves treated with ECSOD and
catalase, catalase or ECSOD relative to the unprotected nerves. As-
terisk (*) represents p<0.05, L represents lumen.
7cular compartment indicated normal integrity of the BBB. Fig-
ure 6 shows representative transmission electron micrographs
of the optic nerve of ECSOD mice inoculated with rAAV-cata-
lase exhibiting less extravasated serum albumin (Figure 6A)
than the control left eyes of wild-type littermates in which
accumulation of extravasated albumin immunogold in the
perivascular space is evident (Figure 6B). AAV-delivered cata-
lase to the right eyes of transgenic ECSOD mice (ECSOD
OD) reduced disruption of the BBB by 63%, with a mean value
of 62 extravasated immunogold particles per 2.6x106 µm2 rela-
tive to the left eyes of wild-type mice (Wt OS) with a mean
value of 167 extravasated immunogold particles per 2.6x106
µm2 (p<0.01; Figure 6C-D). This combined effect was greater
than a value of 108 extravasated immunogold particles per
2.6x106 µm2 for catalase gene transfer to the eyes of wild-type
mice (Wt OD) that suppressed BBB disruption by 35% rela-
tive to unprotected left eyes (Wt OS; p<0.05). It was also
greater than 119 extravasated immunogold particles per
2.6x106 µm2 for the solo effect of germ line increases in
ECSOD (ECSOD OS) that suppressed disruption of the BBB
by 29% relative to untreated left eyes of wild-type littermates
(Wt OS; p<0.05). Thus, combined scavenging of superoxide
by ECSOD and hydrogen peroxide by catalase gene transfer
restored integrity to the BBB.
DISCUSSION
 Our results demonstrate that most parameters of experimen-
tal optic neuritis were substantially ameliorated by genetically
induced expansion of two key antioxidant enzymes, catalase
and ECSOD. Previously, we had demonstrated the beneficial
effects of detoxification of a single ROS (H2O2) by catalase
gene monotherapy. However, catalase only suppressed demy-
elination by 38% [23,30]. Since multiple ROS are likely in-
volved in the pathogenesis of EAE and MS, it was reasonable
to expect that detoxifying several detrimental ROS would have
the best suppressive effect on disease activity. Here by com-
bining ROS scavenging with ECSOD and catalase, we
achieved a 72% reduction in the most important parameter of
EAE studied, myelin injury to the optic nerve. This result was
substantially better than the solo effect of catalase or ECSOD.
Dai and coworkers attempted this approach in an animal model
of antigen-induced arthritis in rodents [40]. In their study com-
©2007 Molecular Vision Molecular Vision 2007; 13:1-11 <http://www.molvis.org/molvis/v13/a1/>
Figure 6. Restoration of blood-brain barrier integrity.  Transmission electron micrographs show that the combined effects of catalase and
ECSOD markedly decreased extravasation of serum albumin labeled by immunogold (arrows) from the vessel lumen into the perivascular
space (A), relative to perivascular accumulation of labeled serum albumin in the unprotected optic nerve (B). The barplot shows mean
extravasated albumin immunogold counts in the retrobulbar optic nerves protected by ECSOD and catalase (ECSOD OD), catalase (Wt OD),
ECSOD (ECSOD OS) or unprotected EAE (Wt OS; C). Barplot (D) illustrates the decrease in extravasated albumin immunogold in nerves
treated with ECSOD and catalase, catalase or ECSOD relative to the unprotected nerves. Asterisk (*) represents p<0.05, double asterisks (**)
represents p<0.01, L represents lumen.
8bined scavenging with ECSOD and catalase did not have an
additive protective effect on arthritis though each antioxidant
gene had a protective effect as in our study, in which each also
suppressed demyelination and disruption of the blood-brain
barrier. Still, we found that the ECSOD did not exert a sup-
pressive effect on optic nerve head swelling. Since optic nerve
head edema is predominantly due to swelling of axons rather
than accumulation of extracellular fluid, lack of intra-axonal
ECSOD likely contributed to the relative lack of protection at
the nerve head.
The linearity of the combined protective effect of ECSOD
and catalase that suppressed blood-brain barrier disruption and
demyelination in our study suggests that superoxide and hy-
drogen peroxide each has a direct detrimental effect on blood
vessels and myelin in the EAE optic nerve. Still, superoxide
and hydrogen peroxide can combine to generate a highly toxic
metabolite, the hydroxyl radical. While scavenging of either
reactant may then suppress hydroxyl radical formation, com-
bined scavenging of either reactant may have no additional
benefit. Clearly, this was not the case here. By detoxifying
H2O2 to relatively nontoxic byproducts the solo effect of cata-
lase was better than that of ECSOD that had the least protec-
tive effect. Several factors may have contributed to this result.
Dismutation of superoxide by ECSOD increased extracellu-
lar H2O2 levels. Our prior publications have demonstrated the
adverse impact of hydrogen peroxide on experimental optic
neuritis [31,41]. Thus, accumulation of H2O2 in the extracel-
lular compartment may have partially dampened the suppres-
sive effect that dismutation of superoxide by ECSOD had on
experimental optic neuritis. Still despite the increase in H2O2,
ECSOD had a modest suppressive effect. In addition, the sup-
pressive effect of ECSOD on experimental optic neuritis may
have occurred perhaps by reducing generation of other patho-
genic ROS. With less superoxide available to react with nitric
oxide, levels of highly toxic peroxynitrite may have been sup-
pressed and levels of nitric oxide increased [42]. Nitric oxide
and peroxynitrite, formed by the reaction of nitric oxide and
superoxide, also play a role in the pathogenesis of EAE and
MS [43-45].
The antioxidant enzymes catalase and SOD can be used
to target ROS for destruction, thus suppress tissue injury. How-
ever, there are limitations to the use of the proteins themselves
as treatment agents in EAE and MS. First, the antioxidant en-
zyme (SOD) must be administered daily, even with conjuga-
tion of polyethylene glycol, to prolong the half-life of the en-
zyme [31,46]. Second, exogenous SOD or catalase are effec-
tive only during the periods of active BBB disruption when
these high molecular weight proteins are able to penetrate the
central nervous system (CNS) [47]. Finally, optic neuritis re-
curs in part due to the inability of the protein to cross the BBB
after integrity is restored.47 Genetic augmentation of cellular
defenses against superoxide and hydrogen peroxide helps sur-
mount these limitations. Since transgene expression follow-
ing delivery with the AAV vector is relatively long-lived, a
single treatment may be sufficient. Still, treatment by intraocu-
lar injection incurs some risk, even with an AAV vector that is
relatively nonpathogenic.
Our findings in acute EAE suggest that genetic amplifi-
cation of cellular defenses against ROS may have a role in
attenuating CNS injury associated with optic neuritis and per-
haps MS. Determining whether comparable levels of protec-
tion are also maintained against the repeated demyelinating
inflammation of chronic relapsing EAE may be key, if anti-
ROS gene transfers are to be applied in a clinical setting. While
the 72% suppressive effect on demyelination achieved here is
promising, our next steps are to tackle the pitfalls inherent in
dual AAV infection of the retina and optic nerve and to dem-
onstrate a protective effect by AAV mediated transfer of both
genes (catalase and SOD), or perhaps even a chimeric SOD
[48] on chronic EAE.
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